Nautilus Biotechnology Inc expected to post a loss of 16 cents a share - Earnings Preview

Nautilus Biotechnology

26/04/2024 15:37

* Nautilus Biotechnology Inc  NAUT.OQ   NAUT.O  is expected
to show no change in quarterly revenue when it reports 
results on April 30 for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Nautilus Biotechnology
Inc is
for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nautilus
Biotechnology Inc is $5.00​, above​ its last closing price
of $2.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.13       -0.14      -0.14     Met     3.4
 Sep. 30 2023  -0.17       -0.17      -0.13     Beat    22.4
 Jun. 30 2023  -0.14       -0.15      -0.13     Beat    13.3​
 Mar. 31 2023  -0.16       -0.17      -0.12     Beat    28
 ​​Dec.        -0.14       -0.15      -0.11     Beat    28.3
 31 2022                                                
 Sep. 30 2022  -0.15       -0.15      -0.11     Beat    25.4​
 Jun. 30 2022  -0.17       -0.17      -0.12     Beat    28.4
 Mar. 31 2022  -0.16       -0.16      -0.13     Beat    17
 This summary was machine generated April 26 at 14:37 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)